Drug utilization, safety and clinical use of Actos and Avandia.

作者: Donald H. Marks

DOI: 10.3233/JRS-120581

关键词:

摘要: AND OBJECTIVE: The impetus for this review was recent increased warnings of cardiovascular toxicity, fractures and bladder cancer associated with glitazone use. METHODS: A drug utilization performed regarding the use Actos (pioglitazone) Avandia (rosiglitazone) at Cooper Green Mercy Hospital (CGMH), an inner city safety net hospital in Birmingham, Alabama. Pharmacy records were reviewed hospital-wide to determine usage patterns all anti-diabetic medications. Medline FDA websites searched articles on efficacy pioglitazone rosiglitazone. Considerations relative profile, comparative efficacy, indications, cost, profile two available medications class. RESULTS: On basis these factors, a switch rosiglitazone prescriptions implemented, which estimated result savings $83,000 first year. No episodes worsening control diabetes anticipated, nor decreased or adverse effects as automatically switching patients from time prescription filling. CONCLUSIONS: conclusions can be summarized number key points.

参考文章(27)
Philip D. Home, Stuart J. Pocock, Henning Beck-Nielsen, Ramón Gomis, Markolf Hanefeld, Nigel P. Jones, Michel Komajda, John J.V. McMurray, Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. The New England Journal of Medicine. ,vol. 357, pp. 28- 38 ,(2007) , 10.1056/NEJMOA073394
L. Azoulay, H. Yin, K. B. Filion, J. Assayag, A. Majdan, M. N. Pollak, S. Suissa, The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study BMJ. ,vol. 344, ,(2012) , 10.1136/BMJ.E3645
Iskandar Idris, Graham Warren, Richard Donnelly, Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes JAMA Internal Medicine. ,vol. 172, pp. 1005- 1011 ,(2012) , 10.1001/ARCHINTERNMED.2012.1938
Asra Kermani, Abhimanyu Garg, Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clinic proceedings. ,vol. 78, pp. 1088- 1091 ,(2003) , 10.4065/78.9.1088
Sonal Singh, Yoon K. Loke, Curt D. Furberg, Long-term Risk of Cardiovascular Events With Rosiglitazone JAMA. ,vol. 298, pp. 1189- 1195 ,(2007) , 10.1001/JAMA.298.10.1189
A. Michael Lincoff, Kathy Wolski, Stephen J. Nicholls, Steven E. Nissen, Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus JAMA. ,vol. 298, pp. 1180- 1188 ,(2007) , 10.1001/JAMA.298.10.1180
Justin E. Bekelman, Yan Li, Cary P. Gross, Scope and Impact of Financial Conflicts of Interest in Biomedical Research: A Systematic Review JAMA. ,vol. 289, pp. 454- 465 ,(2003) , 10.1001/JAMA.289.4.454
Nelson B. Watts, David A. D’Alessio, Type 2 diabetes, thiazolidinediones: bad to the bone? The Journal of Clinical Endocrinology and Metabolism. ,vol. 91, pp. 3276- 3278 ,(2006) , 10.1210/JC.2006-1235
Tracy Hampton, Diabetes drugs tied to fractures in women. JAMA. ,vol. 297, pp. 1645- 1645 ,(2007) , 10.1001/JAMA.297.15.1645
Chia-Hsuin Chang, Jou-Wei Lin, Li-Chiu Wu, Mei-Shu Lai, Lee-Ming Chuang, K. Arnold Chan, Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. ,vol. 55, pp. 1462- 1472 ,(2012) , 10.1002/HEP.25509